Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib with Artemether-lumefantrine in Healthy Participants
NCT04456634Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ruxolitinib in malaria (2 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Number of Participant With Treatment-Related Adverse Events up to 28 days, Number of Participants With Changes of Systolic and Diastolic Blood Pressure up to 28 days and 2 more. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04456634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456634.